Page 2 - Ancer Prostate News Today

When informed about treatment options, most men with low-risk prostate cancer chose active surveillance instead of active therapy in a recent Italy-based analysis.

Preliminary real-world audit data show reduced A1c among men who received testosterone replacement therapy over a 2-year period.

Continuing ADT beyond 6 months does not improve outcomes in men with high-risk localized prostate cancer also receiving brachytherapy and external beam radiation therapy, new research suggests.

A new study identifies three factors associated with PSA failure in men with nonmetastatic unfavorable-risk prostate cancer, revealing who may benefit from treatment escalation.

The use of doublet therapy has increased survival by 6 months, on average, in men with de novo metastatic castration-sensitive prostate cancer, according to Swedish registry data.

Investigators say using diagnostic CT, rather than CT simulation, for palliative radiotherapy planning brings faster pain relief to patients and saves providers time.

For patients with low and favorable intermediate-risk prostate cancer, stereotactic body radiation therapy delivered in five fractions provided similar 5-year disease control as conventional, higher-dose external-beam radiation.

Hospital-based financial navigators may help cancer patients negotiate the intricacies of insurance coverage, experts suggest.

The results of recent studies call into question the traditional views regarding which cancers are typical among adults younger than 50 years.

Fear and a lack of health-related knowledge pose significant barriers to preventive cancer care access and effectiveness.